An orally administered magnoloside A ameliorates functional dyspepsia by modulating brain-gut peptides and gut microbiota

Publication date: 15 September 2019Source: Life Sciences, Volume 233Author(s): Zhenzhen Xue, Changxun Wu, Junying Wei, Minghua Xian, Tingting Wang, Bin Yang, Min ChenAbstractAimsFunctional dyspepsia (FD) is very common worldwide with a high prevalence of 10%–30%, and it becomes a heavy burden to patients because of its hard to be cured. In our previous study, phenylethanoid glycosides were found to exist in Houpo, a traditional Chinese medicine commonly used for the treatment of abdominal distention, pain and dyspepsia. In the present study, the effect of magnoloside A (MA), a main phenylethanoid glycoside in Houpo, on FD was firstly evaluated and its potential mechanism was concluded.Materials and methodsMA was orally administered consequently for 3 weeks, and its effect on a FD rat model established through transient neonatal gastric irritation and mature alternate-day fasting was tested. Levels of brain-gut peptides and inflammatory factors in blood or tissues were determined by ELISA methods. Meanwhile, the gut microbiota was analyzed by 16S rRNA gene sequencing and short chain fat acids were determined by GC/MS.Key findingsMA exhibited anti-FD activities by fastening the delayed gut emptying rate of FD rat and increasing the levels of gastrin, motilin, and calcitonin gene related protein; and decreasing the levels of 5-hydroxytryptamine, nitric oxide synthase, and vasoactive intestinal peptide. On the other hand, MA can modulate the composition of gut microbiota, res...
Source: Life Sciences - Category: Biology Source Type: research